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Monday, February 9, 2015 291anucleotide-gated (CNG) ion channels. CNG channels are cation channels
modulated by cytoplasmic cyclic nucleotides, which play important roles
in sensory signal transduction in eukaryotes. Cell-based assays have accu-
mulated evidence for lipid-modulation of CNG ion channels. To isolate
and systematically study the effect of lipids on CNG channels, we recon-
stituted a model CNG channel into lipid bilayer nanodiscs composed of
phosphocholine, phosphoglycerol and phosphoethanolamine lipids. We char-
acterized these nanodisc preparations using size exclusion chromatography,
electron microscopy and dynamic light scattering to ensure the formation
of nanosized discoidal protein/lipid complexes. The reconstitution of CNG
channels into nanodiscs permits the direct thermodynamic measurement of
cAMP binding to the channel using isothermal titration calorimetry (ITC).
This platform allowed us to probe the binding of cyclic nucleotides to
CNG channels in the presence of different lipids, an important step in under-
standing the molecular mechanism of lipid modulation of CNG channel
gating.Cardiac Muscle Mechanics and Structure I
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Selective alpha7 nicotinic receptor agonists, such as GTS-21, are known to
have neuroprotective and anti-inflammatory actions, but the effect of these
agents on the heart is not known. Therefore, we evaluated the actions
of GTS-21 in isolated atria and isolated hearts from C57BL/6 mice. GTS-21
(1-100 mM) caused a concentration-dependent increase in amplitude of contrac-
tions and decrease in beating rate in isolated atria. Percent changes in rate
and contractile force evoked by 30 mM GTS-21 were 14 5 2 and þ36 5
11, respectively (n ¼ 4). The onset of responses to GTS-21 was slower than
would occur to acetylcholine and norepinephrine, and effects of GTS-21
were not blocked by atropine or atenolol. The impact of GTS-21 on left ventric-
ular function was evaluated next in isolated hearts paced at 400 BPM. Treat-
ment with 30 mM GTS-21 caused significant increases in contractile
function: developed pressure (þ30 5 4%); peak systolic pressure (þ16 5
2%); dP/dtmax (þ31 5 6%). Diastolic pressure was also decreased (60 5
10%) while the rate of relaxation increased (-dP/dtmax, þ36 5 6%) with no
sizable change in coronary perfusion pressure (p < 0.05 for all parameters,
n ¼ 4). Surprisingly, responses to GTS-21 were not affected by a selective
alpha7 antagonist or the nonselective nicotinic antagonist mecamylamine,
and there was no evidence of desensitization. Our data demonstrate that GTS
enhances atrial and ventricular contractility and improves LV relaxation with
a modest decrease in heart rate. GTS-21 cardiac actions occur by a mechanism
that is independent of nicotinic receptors and autonomic nerves. The unique
profile of cardiac effects for GTS-21 suggests its potential use in the setting
of acute heart failure.
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No drugs are capable to prevent phenotype development and adverse cardiac
remodeling in hypertrophic cardiomyopathy (HCM). Ranolazine, a late Naþ
current blocker, reduced arrhythmogenicity and improved relaxation in
cardiomyocytes and trabeculae from HCM patients (Coppini et al., Circula-
tion 2013). Employing a transgenic mouse model carrying the HCM-
associated R92Q mutation in the TNNT2 gene, we previously showed that
acute in vitro treatment with ranolazine is capable to reverse some electro-
mechanical alterations, including the prolonged kinetics of Ca2þ transients,
the higher diastolic [Ca2þ] and the increased frequency of arrhythmogenic
spontaneous activity (Pioner et al., Biophys J 2014, 106, 644a). Here we em-
ployed the same mouse model to assess whether long-term oral treatment
with ranolazine since birth is capable to prevent the HCM phenotype and
the associated myocardial remodeling. We compared the behavior of WT,R92Q-untreated and R92Q-treated 1 year old mice. Echocardiographic mea-
surements showed that the R92Q-treated in vivo hearts lacked the left ven-
tricular hypertrophy, hypercontractility and diastolic dysfunction found in
the R92Q-untreated mice. Gadolinium-contrast magnetic resonance showed
that the intramyocardial fibrosis of the R92Q-untreated hearts was largely
reduced in the treated mice.Both amelioration of cardiomyocyte function
and reduction of extracellular fibrosis may contribute to the positive effect
of the long-term treatment with ranolazine that could represent a candidate
for preventive treatment of phenotype-negative mutation carriers. Mechani-
cal experiments in intact left and right ventricular trabeculae confirmed the
alterations we had previously reported in R92Q-untreated mice compared to
WT and showed that those alterations were mostly reversed in the R92Q-
treated mice. In the R92Q-treated preparations the inotropic response to
isoproterenol was preserved and the occurrence of spontaneous activity
was markedly reduced compared to the untreated trabeculae and was com-
parable to that of WT trabeculae.
1461-Pos Board B412
Stage-Dependent Benefits and Risks of Pimobendan in Genetic Dilated
Cardiomyopathy Mice with Progressive Heart Failure
Miki Nonaka1, Takashi Murayama2, Nagomi Kurebyashi2, Lei Li1,
Yuan-Yuan Wang1, Sachio Morimoto1.
1Kyushu University, Fukuoka, Japan, 2Juntendo University, Tokyo, Japan.
The Ca2þ sensitizer pimobendan is a unique inotropic agent that, compared
with traditional inotropes, improves cardiac contractility with less oxygen
consumption and potentially fewer adverse effects on myocardial remodelling
and arrhythmia. However, clinical trials report contradictory effects of pimo-
bendan in heart failure (HF) patients. We provide mechanistic experimental
evidence of the efficacy of pimobendan using a novel mouse model of pro-
gressive HF.A knock-in mouse model of human genetic dilated cardiomyop-
athy, which shows a clear transition from compensatory to end-stage HF at a
fixed time during growth, was used to evaluate the efficacy of pimobendan
and explore the underlying molecular and cellular mechanisms.Pimobendan
prevented myocardial remodelling in compensated HF and significantly
extended the life span in both compensated and end-stage HF, but dose-
dependently increased the sudden death in end-stage HF. In cardiomyocytes
isolated from end-stage HF mice, pimobendan induced triggered activity
probably due to early or delayed afterdepolarizations via markedly up-
regulated electrogenic sodium/calcium exchanger 1 activation. The L-type
Ca2þ channel blocker verapamil decreased the incidence of triggered activity,
suggesting that this was from overly elevated cytoplasmic Ca2þ through
increased Ca2þ entry by phosphodiesterase 3 inhibition under diminished
sarcoplasmic reticulum Ca2þ reuptake and increased Ca2þ leakage from
sarcoplasmic reticulum in end-stage HF.Pimobendan is beneficial irrespective
of HF stage, but increases sudden cardiac death in end-stage HF with exten-
sive remodelling ofCa2þ handling. Reduction of cytoplasmic Ca2þ elevated
by phosphodiesterase 3 inhibition may decrease the risk of sudden cardiac
death.
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Impaired cGMP-PKG signaling may contribute to cardiomyocyte remodel-
ing and cardiac dysfunction in heart failure with preserved ejection fraction
(HFpEF) patients. The purpose of this study was to assess cardiomyocyte
function and morphology in aortic-banded mini-swine displaying a HFpEF
phenotype following manipulation of cGMP signaling via two mechanisms:
1) driving cGMP synthesis with the DPP4 inhibitor saxagliptin; and 2)
preventing cGMP catabolism via the PDE5 inhibitor tadalafil. We hypothe-
sized that preserving cGMP-PKG signaling would prevent cardiomyocyte
dysfunction and remodeling. Contractile function was measured in enzymat-
ically isolated cardiomyocytes electrically stimulated at three frequencies
(0.25, 0.5, 1.0 Hz)from four groups: control (CON), aortic-banded (AB),
AB saxagliptin-treated (AB-SAX), and AB tadalafil-treated (AB-TAD).
Increased cGMP activity was only observed in AB-TAD animals, however,
neither drug treatment increased PKG activity. A significant pacing-induced
decrease in diastolic sarcomere length was observed in the AB and AB-TAD
groups compared to CON. This finding, indicative of impaired diastolic
relaxation, was prevented by saxagliptin treatment. Shortening amplitude
292a Monday, February 9, 2015decreased in AB cardiomyocytes with increasing pacing frequency, re-
vealing a negative shortening-frequency relationship that was attenuated
by both drug treatments. Length:width ratio was decreased in AB and
AB-TAD animals with commensurate decreases in left ventricular (LV)
end diastolic and end systolic volumes. Normal cardiomyocyte size and
LV volumes were preserved in the AB-SAX group. Interestingly, all AB
groups exhibited similar gross hypertrophic remodeling (heart weight:body
weight ratio) despite differences in cardiomyocyte morphology. In conclu-
sion, saxagliptin appears superior for preserving normal cardiomyocyte
morphology and overall function versus tadalafil, independent of changes
in cGMP-PKG activity.
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Quercetin (3, 30, 40, 5, 7-pentahydroxyflavone, QCT) is a major flavonoid of
plants, known to exhibit anti-oxidative, anti-inflammatory, and anti-cancer
effects. QCT has been demonstrated to have a cardioprotective effect
through its antioxidant activity. In the present study, we found that QCT
markedly enhanced the contractility of a single cardiomyocyte isolated
from mouse hearts in a dynamic fashion even under conditions with no
apparent oxidative stress. Simultaneous measurement of Ca2þ transient in
a Fura-2 loaded single cardiomyocyte revealed that QCT markedly increased
the cytoplasmic Ca2þ both at diastole and systole under regular electrical
stimulation. Echocardiography revealed that intravenous administration of
QCT also increased the left ventricular systolic function of the heart evalu-
ated by ejection fraction in mice with reduced cardiac function due to a mu-
tation causing genetic dilated cardiomyopathy (delK210 mutation in cardiac
troponin T). QCT did not change the maximum force-generating capability
and Ca2þ sensitivity of force generation in skinned (membrane-permeabi-
lized) cardiac muscle fibers prepared from mouse hearts, indicating that
QCT has no direct effects on the contractile machinery in cardiomyocytes.
These findings indicates that QCT has a direct cardiotonic effect through
enhancing the Ca2þ transient in cardiomyocytes independently of its anti-
oxidative action. Studies on the molecular mechanisms underlying these phe-
nomena are in progress.
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We examined the relationships between troponin I phosphorylation and Ca2þ-
regulation of contractility in single myofibrils from a mouse model of famil-
ial DCM (ACTC E361G) in comparison with non-transgenic (NTG) . We
measured the effects of changing [Ca2þ] and troponin I phosphorylation level
on myofibril contractility. Propranolol treatment of mice was used to reduce the
level of troponin I in their hearts prior to isolating the myofibrils.
For non-transgenic mouse myofibrils we found that when the TnI phosphoryla-
tion level was reduced from 1.02 to 0.3 the Ca2þ-sensitivity of force was
increased (EC50P/unP¼1.8), relaxation parameter kREL was reduced and tLIN
was increased. ACTCE361G mouse myofibrils were uncoupled: Ca2þ-sensi-
tivity and relaxation parameters did not depend on troponin I phosphorylation
level (EC50P/unP¼0.88). Nevertheless, modulation of Ca2þ-sensitivity by
sarcomere length or due to EMD57033 was retained.
The Ca2þ-desensitiser Epigallocatechin-3-gallate (EGCG) decreased Ca2þ-
sensitivity in phosphorylated and unphosphorylated NTG myofibrils equally
(EC50 P/uP¼ 0.5050.06 and 0.4550.07 respectively) but did not change
the relaxation parameters tLIN and kRE. The rate of force development
(kACT), measured at high Ca
2þ, was unchanged in myofibrils with phosphory-
lated TnI and 22% decreased in unphosphorylated myofibrils indicating that
EGCG affects cross-bridge activation kinetics.
EGCG reduced Ca2þ-sensitivity and kACT in both phosphorylated and unphos-
phorylated ACTCE361G myofibrils. The change in EC50 was more in phos-
phorylated than unphosphorylated myofibrils, consequently EGCG restored
the lost difference in EC50 values between phosphorylated and unphosphory-
lated myofibrils and also the difference in relaxation parameters tLIN and
kREL. The observation that EGCG does not affect either the EC50 P/ EC50unP or tLIN in NTG myofibrils but changes them in ACTG E361G suggests
that EGCG can restore modulation of cardiac contractile function by TnI phos-
phorylation to DCM mutant myofibrils independently of its Ca2þ-desensitising
function.
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Whole exon sequence data from 28 FDCM patient cardiac muscle samples was
screened for potentially disease-causing mutations in 58 genes previously
implicated in HCM or DCM . We identified OBSCN gene mutations in 5 sam-
ples; one sample had two OBSCN mutations, one also had a DSP mutation and
another also had a SCN5A mutation Also identified were 6 truncating muta-
tions in TTN, 3 mutations in MYH7, 2 in DSP and one each in TNNC1,
TNNI3, MYOM1, VCL, GLA, PLB, PKP2 and LAMA4 .
The mean level of obscurin mRNA was significantly greater and more variable
in donor samples than the FDCM samples (1.6950.53, n¼58 compared with
0.5750.10,n¼ 68, p¼0.0025). The mRNA content of FDCM samples was
not significantly different with and without OBSCN mutations.
The obscurin protein band was estimated to be <1% of the abundance of
titin; it was identified and quantified with antibodies. The apparent mass
was 9605 60 kDa. The OBSCN mutation samples had levels of expres-
sion, significantly different from FDCM samples without obscurin muta-
tions, donor hearts or myectomies. Four OBSCN mutant samples exhibited
low levels of obscurin protein (48, 61, 51,and 70% of the level in control
FDCM samples). One OBSCN mutant sample exhibited 34% more
expression.
Immunofluorescence microscopy using obscurin, myomesin and a-actinin-spe-
cific antibodies showed that obscurin was located at the level of the M-line and
preferentially labelled the sides of the myofibrils. There was no apparent differ-
ences between wild-type and mutant samples.
Mutations in the obscurin gene should be considered as a significant cause
of FDCM, alone or in concert with another mutation. Disease-related OBSCN
mutations cause demonstrably abnormal expression in myofibrils that could
account for the development of a DCM phenotype.
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Thyroid hormones are key regulators of basal metabolic state and oxidative
metabolism. Hyperthyroidism has been reported to cause significant alter-
ations in hemodynamics, and cardiac and diaphragm muscle function,
all which have been linked to increased oxidative stress. Previously, we
have shown that thyroxin (T4) treatment in mice resulted in hypertension,
increased cardiac reactive oxygen species (ROS), cardiac hypertrophy,
and cardiac contractile dysfunction. Here, we sought to investigate the
functional impact of T4 on diaphragm muscle function as well as to iden-
tify the role and the source(s) of ROS in these distinct phenotypes of
our model. Wild-type and T4 mice with and without 2-week treatments
with allopurinol (xanthine oxidase inhibitor), apocynin (NADPH-oxidase
inhibitor), L-NIO (nitric oxide synthase inhibitor), or MitoTEMPO (mito-
chondria-targeted antioxidant) were studied. Blood pressure and echocardi-
ography were non-invasively evaluated, followed by ex-vivo assessments
of isolated heart and diaphragm muscle functions. Treatment with L-NIO
attenuated the T4-induced hypertension in mice. However, apocynin im-
proved the left ventricular (LV) dysfunction without preventing the cardiac
hypertrophy in these mice. Both allopurinol and MitoTEMPO reduced the
T4-induced fatigability of the diaphragm muscles. In conclusion, we show
here for the first time that T4 exerts differential effects on various sources
of ROS to induce distinct cardiovascular and skeletal muscle phenotypes.
Additionally, we find that T4-induced LV dysfunction is independent
of cardiac hypertrophy, while NADPH-oxidase is a key player in this pro-
cess. Furthermore, we prove the significance of both xanthine-oxidase
and mitochondrial ROS pathways in T4-induced fatigability of diaphragm
muscles.
